New Breast Cancer Drug Defeats the Ras Genes Notorious for Causing Many Types of Cancer

Newsfeed Image, Light Gray Text On Dark Gray Background
Blocking the function of the Ras oncogenes is considered by many scientists to be the “holy grail” of cancer therapeutics because mutations in these genes drive the growth of so many different types of cancers. The three Ras genes found in humans — H-Ras, K-Ras and N-Ras — were among the first to be linked to cancer development, and a new study led by VCU Massey Cancer Center researcher Paul Dent, Ph.D., has shown the recently approved breast cancer drug neratinib can block the function of Ras as well as several other oncogenes through an unexpected process.
Read more . . .